OLMA

Olema Pharmaceuticals Inc

OLMA, USA

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal Phase 3 clinical trial of palazestrant as a monotherapy in second/third-line ER+/HER2- metastatic breast cancer; and palazestrant with CDK4/6 inhibitors palbociclib and ribociclib, a phosphatidylinositol 3 kinase alpha (PI3Ka) inhibitor alpelisib, and with an mTOR inhibitor everolimus that is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer. It also develops OP-3136, an orally-available small molecule that potently and selectively inhibits KAT6 for patients with ER+/HER2- metastatic breast cancer and other cancers which is in Phase 1 clinical trial. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

https://olema.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
OLMA
stock
OLMA

Olema Pharmaceuticals (OLMA): Reassessing Valuation After Roche’s Phase 3 SERD Success Boosts Palazestrant Expectations simplywall.st

Read more →
OLMA
stock
OLMA

Oppenheimer Raises Price Target for Olema Pharmaceuticals (OLMA) to $48 | OLMA Stock News GuruFocus

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$36.5

Analyst Picks

Strong Buy

5

Buy

3

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

8.94

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-13.73 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-11.98 %

Low ≤ 2%

High ≥ 10%

Debt to Equity

-

Very High

0.15

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 107.97% of the total shares of Olema Pharmaceuticals Inc

2.

Paradigm Biocapital Advisors LP

(9.8554%)

since

2025/06/30

3.

Bvf Inc

(7.7161%)

since

2025/06/30

4.

BlackRock Inc

(6.7096%)

since

2025/06/30

5.

Woodline Partners LP

(5.1081%)

since

2025/06/30

6.

Deep Track Capital, LP

(5.0162%)

since

2025/06/30

7.

Vanguard Group Inc

(4.76%)

since

2025/06/30

8.

Logos Global Management LP

(4.6753%)

since

2025/06/30

9.

HHG PLC

(4.4042%)

since

2025/06/30

10.

Franklin Resources Inc

(4.3884%)

since

2025/06/30

11.

MPM Oncology Impact Management LP

(3.4658%)

since

2025/06/30

12.

Vanguard Total Stock Mkt Idx Inv

(2.8558%)

since

2025/07/31

13.

Lightspeed Management Co LLC

(2.8133%)

since

2025/06/30

14.

Pictet Asset Manangement SA

(2.7377%)

since

2025/06/30

15.

Citadel Advisors Llc

(2.4887%)

since

2025/06/30

16.

Vivo Capital, LLC

(2.194%)

since

2025/06/30

17.

iShares Russell 2000 ETF

(2.1141%)

since

2025/08/31

18.

Morgan Stanley - Brokerage Accounts

(2.0943%)

since

2025/06/30

19.

UBS Group AG

(2.0574%)

since

2025/06/30

20.

Geode Capital Management, LLC

(1.9322%)

since

2025/06/30

21.

Franklin Biotechnology Discv A(acc)USD

(1.926%)

since

2025/08/31

22.

Millennium Management LLC

(1.852%)

since

2025/06/30

23.

Dimensional Fund Advisors, Inc.

(1.7588%)

since

2025/06/30

24.

Pictet-Biotech P USD

(1.3572%)

since

2025/05/31

25.

Franklin US Small Cap Growth Equity

(1.3372%)

since

2025/06/30

26.

Franklin Small Cap Growth Adv

(1.3014%)

since

2025/07/31

27.

Belfius Equities Cure C Cap

(1.2391%)

since

2025/08/31

28.

Pictet-Global Megatrend Sel I USD

(1.1593%)

since

2025/05/31

29.

Columbia Small Cap Value Discv A

(1.1344%)

since

2025/07/31

30.

Franklin Biotechnology Discovery A

(1.1251%)

since

2025/07/31

31.

Columbia Small Cap Value Discovery Fund

(1.1033%)

since

2025/06/30

32.

International Biotechnology Ord

(0.9007%)

since

2025/07/31

33.

Fidelity Small Cap Index

(0.8717%)

since

2025/06/30

34.

iShares Russell 2000 Value ETF

(0.7525%)

since

2025/08/31

35.

Vanguard Institutional Extnd Mkt Idx Tr

(0.7468%)

since

2025/07/31

36.

iShares Biotechnology ETF

(0.4501%)

since

2025/08/31

37.

Vanguard Russell 2000 ETF

(0.4157%)

since

2025/07/31

38.

Pier Capital Small Cap Growth Equity

(0.4027%)

since

2025/06/30

39.

SEB Nordamerikafond Småbolag

(0.3932%)

since

2025/07/31

40.

Fidelity Extended Market Index

(0.3823%)

since

2025/07/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

-0.5387

Latest Release

Date

2025-09-30

EPS Actual

-0.49

EPS Estimate

-0.4702

EPS Difference

-0.0198

Surprise Percent

-4.211%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(3)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.8)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(0.5)
Momentum
No Momentum(2)
Net Net
Not Undervalued (Net-Net)(1)
Quality
Low Quality Business(2.5)
Value
Overpriced(3)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.